摘要
多巴胺受体分为5个亚型,包括D1、D2、D3、D4以及D5,其中,多巴胺D3受体(D3R)主要分布在与情感、认知密切相关的边缘脑区,是精神分裂症、帕金森氏症、运动障碍及药物成瘾等相关疾病的潜在治疗靶点,高亲和力和高选择性D3R配体的研究是药物研究热点之一。一些具有较高亲和力和选择性的D3R配体,例如,BP 897、NGB 2904、SB-277011-A等已完成了临床前研究,初步显示以D3R为靶点治疗相关疾病的功效和优势。然而,现有选择性D3R配体普遍存在水溶性差、生物利用度不高的缺点,结合药理实验和新药研发需要,本论文设计合成了一系列具有自主知识产权的高亲和力和选择性且类药性较好的D3R拮抗剂。
本论文研究工作和结果如下:
1.本课题以已报道的18个具有较高亲和力和选择性的D3R配体为基础,建立了D3R选择性配体的药效团模型,模型表明该类化合物共有的药效特征包括头尾2个芳环作用端(A与B)、1个氢键受体及1个质子化氮作用中心,其中,芳环A与B之间距离约10?。在此基础上,我们将该药效特征作为D3R定向库设计的限定条件,以期提高筛选命中率。同时,考虑“类药性”改善是当前D3R拮抗剂研究的重要方向,在组合库设计过程中,我们以“优势结构方法”(Privileged Structure Approach)为指导,在芳环A端选择“类药性”极佳的苯并噁(噻)唑啉-2-酮类作为构建单元。此外,在保证重要药效特征的基础上,还选择了4-羟基-喹啉、喹啉和二茂铁类作为芳环A端的构建单元。芳环B端首次选择了已商品化的1-(5-氯-2-甲基-苯基)哌嗪作为构建单元。中间连接链结构相对保守,主要选择易于合成的四亚甲基,并在其中引入了顺式、反式双键作为空间限制以考察空间构型改变对化合物活性的影响。
2.在合成路线设计和方法选择中,我们主要以定向多样性合成(Diversity-Oriented Synthesis)策略为指导,以期通过单一反应实现多个目标化合物的衍生合成,从而提高合成效率和组合库分子的多样性。本研究完成了苯并噁(噻)唑啉-2-酮、羟基-喹啉、喹啉和二茂铁4个系列目标化合物的合成工作,共得到37个全新目标化合物,结构经核磁共振(1H NMR,13C NMR和1D NOESY)、质谱(MS)、红外光谱(IR)确证,HPLC对其纯度进行了分析,所有化合物纯度达98%以上。CA网络版(SciFinder)检索证实为新化合物,已对“系列4”苯并噁(噻)唑啉-2-酮类化合物申请专利保护(专利申请号:200810167089.5)。
3.油水分配系数(LogP)是反映化合物水(脂)溶性大小的重要参数,针对现有多巴胺D3受体选择性配体水溶性差、生物利用度不高的缺点,本课题在D3R选择性拮抗剂的设计过程中,着重强调目标化合物水溶性的提高。因此,建立快速、可靠的实验方法以对目标化合物LogP值进行早期、快速、可靠的测定对指导后期化合物的设计与优化具有重要意义。本研究根据“非经典”阴离子对试剂—三氟乙酸的特殊性质,建立了一种反相离子对色谱方法(RP-IPC),该方法测定范围广,满足了结构中同时含有碱性可质子化氮原子和酸性酰胺官能团的目标化合物测定要求,并成功应用于计算方法不能预测的二茂铁类化合物LogP值快速测定。测定结果显示,除“系列3”二茂铁甲酰胺衍生物“类药性”较差(LogP>5),其余3个系列化合物LogP值均在2-5范围内。
4.在D3R和D2R百分抑制率初步筛选基础上,以稳定转染的D3R-CHO和D2R-HEK-293细胞株为载体,通过放射性配体([3H]spiperone)竞争结合实验,分别测定了目标化合物对D3R、D2R的亲和力和选择性。结果表明,“系列4”中所测定化合物大部分显示极佳的D3R亲和力(Ki,D3R)和选择性(Rs=Ki,D2R/Ki,D3R),其中2个化合物Y-QA14和Y-QA33对D3R具有皮摩尔级亲和力和选择性,远远高于所有已报道亲和力和选择性最高的化合物。Y-QA14对D3受体Ki值为5.2×10-5 nM,对D2受体Ki值为134.5 nM,Rs=2.58×106;Y-QA33对D3R、D2R的亲和力和选择性分别为8.25×10-5 nM,3.063 nM和3.7×104,远远高于阳性对照NGB 2904(Ki,D3R=1.26 nM,Ki,D2R =149.2 nM;Rs= 118)。值得注意的是,Y-QA14和Y-QA33均显示对D3R具有高、低两个亲合位点,药理功能性实验研究表明,Y-QA14可以剂量依赖的拮抗激动剂喹吡罗(Quinpirole,10μM)的激动活性,为D3R选择性拮抗剂,且拮抗作用主要对应于高亲和力位点。
5.药效学评价方面,考察了Y-QA14对小鼠条件性位置偏爱的影响,在吗啡点燃的小鼠条件性位置偏爱实验中,与盐水组相比,YQA14在0.1mg/kg和5mg/kg两个剂量时可以显著对抗吗啡点燃的条件位置偏爱的重现(*P<0.01),表明YQA14对吗啡造成的精神依赖有确定的抑制作用。
6.重点对“系列4”苯并噁(噻)唑啉-2-酮类化合物进行了初步的构效关系分析,结合同源模建和分子对接研究,对得到的活性筛选数据进行了合理性的阐述,结果表明构效关系和分子对接模拟对部分活性筛选结果的阐述具有一定的一致性。在两者联合应用下,确定了该类化合物结构中一个重要的活性官能团(内酰胺),分别在受体结合水平和配体电性特征方面对其进行了较为详细的分析和讨论。此外,确定了该系列化合物以反式构型或自由度较大的直链烷烃作为连接部分对保持高亲和力和选择性有利。
The dopamine receptors have been found five receptor subtypes so far, which are divided into two receptor families, D1-like (D1 and D5) and D2-like (D2, D3, and D4). Among them, dopamine D3 receptor (D3R) is preferentially located in limbic brain regions which have an impact on emotional and cognitive functions.Various pharmacological studies have investigated the D3 system as an interesting therapeutic target for the treatment of schizophrenia, Parkinson's disease, drug-induced dyskinesia and drug abuse (in particular cocaine addiction). D3R ligands with high affinity and selectivity have been an active field of drug research in recent years. During the last decade, some of the compounds (e.g. BP 897, NGB 2904, SB-277011-A) that demonstrate both high affinity and selectivity for D3R have shown the potential for development of D3R antagonists and partial agonists as medications for treatment of the diseases related to D3R dysfunction. However, the poor aqueous solubility and limited bioavailability is always a major limitation for these described potent and selective D3R ligands and an obstacle for evaluation on these novel agents in behavioral animal models and their therapeutic potential. In this research, a series of novel compounds, with high selectivity and affinity for D3R in combination with impressive“drug-likeness”, has been designed and synthesized to meet the requirements of pharmacological research and potential drug development.
The major results of our work can be summarized as follows:
1.To increase the hits of candidates in the D3R-oriented combinatory library, a pharmacophore mode, which has been developed based on eighteen reported compounds that showed high affinity and selectivity for D3R, was applied as the filter standards. According to the model, all of the tested compounds bear the common features: two aromatic or heteroaromatic, one hydrogen donor, one hydrogen acceptor and one protonated center (basic group), and can be formulated as A-L-B, wherein, group A is the head with an aromatic ring bearing a hydrogen acceptor, group B is the tail with an aromatic ring conjugated with a basic group, and L is the linker between A and B which represents an alkyl-spacer with length about four methylene. Moreover, to increase the“drug-likeness”of our target compounds, the 2(3H)-benzox(thi)azolinone scaffolds was selected as an aromatic ring of group A in the combinatory library design inspired by the privileged structure approach. In addition, other building blocks such as 4-hydroxy-quinoline, quinoline, and ferrocene were incorporated into group A for our combinatory library design, alternativly. Furthermore, 1-(5-chloro-2-methylphenyl)piperazine was first selected as the groug B in D3R ligand design. Finally, in search for the potential effects of conformational changes, the semi-rigided 2-trans-butene-1,4-diyl and 2-cis-butene- 1,4-diyl were introduced as the linker (-L-) in addition to butan-1,4-diyl.
2.Aim to obtain diversity of our target compounds with a single efficient round, the“diversity-oriented synthesis”approach is applied during our design and synthesis. Guided by this concept, thirty-seven compounds that belong to four series, respectively incorporated 2(3H)-benzox(thi)azolinone, 4-hydroxyquinoline, quinoline and ferrocene in group A , were synthesized and evaluated selectivity and affinity for D3R. All of the compounds synthesized are new chemical entities according to the search results of SciFinder, and the 2(3H)-benzox(thi)azolinone derivates of the forth serie has applied for patent protection (Application No, 200810167089.5). All compounds synthesized were characterized by their 1H NMR, 13C NMR,1D NOESY, MS and IR spectrum and further submitted to the HPLC analysis, the found purity is above 98% for the test compounds.
3.The n-octanol/water partition coefficient (LogP) is widely used to represent molecular hydrophobicity or lipophilicity. It is of most important to increase the hydrophilicity of the target compounds in our research for developing novel dopamine D3 receptor antagonists with regard to the poor aqueous solubility and limited bioavailability of the reported ligands. To predict and monitor the LogP of our target compounds rapidly, we established a reversed phase ion-pair chromatography (RP-IPC) method based on the exceptional attributes of trifluoroacetic acid behaved as nonclassic ion-pair agents, which is applicable to determine the LogP values of the target compounds with wide pKa range, including both acidic amide groups and basic species or incorporated metal Fe atom in the structure, some of them can not be predicted by computer method. All of the target compounds except for ferrocene derivates show optimal“druglike”profiles as monitered by their LogP values, fallen between 2-5.
4. Competition binding assays were employed to analyze affinity and selectivity profiles of the target compounds to the dopamine D2 and D3 receptors. The binding data was generated by measuring their ability to compete with [3H]-spiperone binding to the cloned human dopamine receptor subtypes D2 and D3 stably expressed in HEK-293 and Chinese hamster ovary cells (CHO). Most of the compounds in serial four showed impressively high affinity (Ki,D3R) and selectivity (Rs= Ki,D2R/ Ki,D3R) for the D3 receptor as compared to the control compound NGB 2904 (Ki,D3R =1.26 nM, Ki,D2R =149.2 nM; Rs=118). To the best of our knowledge, two new compounds can be identified as the best D3R ligands so far, which showed pico-molar binding affinity for D3R. For example, Y-QA14 displayed Ki value of 5.2×10-5 nM and 134.5 nM at human dopamine D2 and D3 receptors, respectively, with Rs of 2.58×106. Y-QA33 was somewhat weaker with Ki,D3R of 8.25×10-5 nM, Ki,D2R of 3.063 nM and Rs of 3.7×104.
It is interesting to note that either Y-QA14 or Y-QA33 has two binding sites referring to the high- and low-affinity binding site, respectively. Further evaluation showed that compound Y-QA14 is a potent D3R antagonist and its antagonist activity is most responded to the high-affinity binding site as tested in a quinpirole-stimulated mitogenesis assay for functional activity at expressed human D3R in CHO cells.
5. Further investigation was carried out in a conditioned place preference (CPP) paradigm, in which Y-QA14 showed substantial antagonist effects for morphine induced CPP at both the concentration of 0.1mg/kg and 5mg/kg(*P<0.01) intraperitoneally (i.p.).
6. In this article, a good agreement between the results of structure activity relationship (SAR) and the observation in molecular docking is obtained for some of the test 2(3H)-benzox(thi)azolinone derivates that belong to the fourth series, and an important pharmacophore is identified and further validated according to the potential model of receptor binding and the form of charge distribution. In addition, introduction of a semi-rigid cis-butene linker into the library decrease the binding affinity and selectivity at the D3R as compared to the trans-butene linker and flexible butylene linker counterpart.
引文
[1] Bouthenet M.L, Souil E, Martres M.P et al. Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry:comparison with dopamine D2 receptor mRNA[J]. Brain Res Rev,1991, 564 (2):203-219.
[2]和友,金国章,多巴胺D3受体(D3R)的神经科学新进展[J],生命科学, 2005, 2(17): 170-175。
[3] Pilon C, Lévesque D, Dimitriadou V, et al. Functional coupling of the human dopamine D3 receptor in a transfected NG 108-15 neuroblastoma-glioma hybrid cell line[J]. Eur J Pharmacol, 1994, 268(2): 129-139.
[4] Baldwin J.M, Schertler G.F, Unger V.M. An Alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors[J]. J Mol Biol. 1997, 272: 144-164.
[5] Toshima H, Fox B, Teller D.C, et al. Crystal structure of rhodopsin: a G protein-coupled receptor[J]. Science, 2000, 289: 739-745.
[6] Boeckler F, Gmeiner P. The structural evolution of dopamine D3 receptor ligands: Structure-activity relationships and selected neuropharmacological aspects[J]. Pharma Therap, 2006, 112: 281-333.
[7] Shalev U, Grimm J.W, Shaham Y. Neurobiology of relapse to heroin and cocaine seeking[J]. Pharmacol Rev,2002, 54 (1):1-42.
[8] Segal D.M, Moraes C.T, Mash D.C. Up-regulation of D3 dopamine receptor MRNA in the nucleus accumbens of human cocaine fatalities [J]. Brain Res Mol Brain Res, 1997, 45(2): 335-339.
[9] Neisewande J.L , Fuchs R.A, Nguyen L., et al. Increases in dopamine D3 receptor binding in rats receiving a cocaine challenge at various time points after cocaine self-administration: implications for cocaine seeking behavior[J]. Neuropsychopharmacology, 2004, 29(8): 1479-1487.
[10] Luedtkea R.R, Mach R.H. Progress in developing D3 dopamine receptor ligands as potential therapeutic agents for neurological and neuropsychiatric disorders[J].Curr Pharm Design, 2003, 9(8):643-671.
[11] Heidbreder C.A, Gardner E.L, Xi Z.X, et al. The role of central dopamine D3 receptors in drug addiction:a review of harmacological evidence[J]. Brain Res Rev,2005,49(1):77- 105.
[12] Reavill C, Taylor S.G, Wood M.D, et al. Pharmacological actions of a novel, high- affinity, and selective human dopamine D3 receptor antagonist, SB-277011-A[J]. J Pharmacol Exp Ther, 2000, 294: 1154-1165.
[13] Stemp G, Ashmeade T, Branch C.L, et al. Design and synthesis of trans-N-[4-[2-(6- cyano-1,2,3,4-tetrahydro-isoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide(SB-277011): A potent and selective dopamine D3 receptor antagonist with high oral bioavailability and CNS penetration in the rat [J]. J Med Chem, 2000, 43: 1878-1885.
[14] Xi Z-X, Gilbert J, Campos A.C, et al. Blockade of mesolimbic dopamine D3 receptors inhibits stress-induced reinstatement of cocaine-seeking in rats[J]. Psychopharmacology (Berlin), 2004, 176: 57-65.
[15] Vorel S.R, Ashy C.R, Paul M, et al. Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats[J]. J Neurosci, 2002, 22: 9595-9603.
[16] Thanos P.K, Katana J.M, Ashby C.R, et al. The selective dopamine D3 receptor antagonist SB-277011-A attenuates ethanol consumption in ethanol preferring (P) and non-preferring (NP) rats[J]. Pharmacol Biochem Behav, 2005, 81(1): 190-197.
[17] Jenner P. Pharmacology of dopamine agonists in the treatment of Parkinson’s disease[J]. Neurology, 2002, 58(1):1-8.
[18] Bezard E, Ferry S, Mach U, et al. Attenuation of levodopa induced dyskinesia by normalizing dopamine D3 receptor function[J]. Nat Med, 2003, 9(6):762-767.
[19] Bettinetti L, Schlotter K, Hubner H, et al. Interactive SAR studies: rational discovery of superpotent and highly selective dopamineD3 receptor antagonists and partial agonists[J]. J Med Chem, 2002, 45(21): 4594-4597.
[20] Boeckler F, Leng A, Mura A, et al. Attenuation of 1-methyl-4-phenyl- 1,2,3,6- tetra-hydropyridine (MPTP) neurotoxicity by the novel selective dopamine D3 receptor partial agonist FAUC329 predominantly in the nucleus accumbens of mice[J]. Biochem Pharma-col, 2003, 66(6): 1025-1032.
[21] Joyce J.N, Millan M.J. Dopamine D3 receptor antagonists as therapeutic agents[J]. Drug Discov Today, 2005, 10(13): 917-925.
[22] Bressan R.A, Erlandsson K, Jones H.M, et al. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect: An in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients[J]. Am J Psychiatry, 2003, 160(8): 1413-1420.
[23] Strange P.G. Anti-psychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects[J]. Pharmacol Rev, 2001, 53(1): 119-133.
[24] Staddon S, Arranz M.J, Mancama D, et al. Association between dopamine D3 receptor gene polymorphisms and schizophrenia in an isolate population[J]. Schizophr Res, 2005, 73(1): 49-54.
[25] Dubuffet T, Tancredi A.N, Cussac D, et al. Novel benzopyrano [3,4-c]pyrrole derivatives as potent and selective dopamine D3 receptor antagonists[J]. Bioorg Med Chem Lett, 1999, 9(14): 2059-2064.
[26] Snider S.R, Kuche O. Dopamine: an important neurohormone of the sympathoadrenal system: significance of increased peripheral dopamine release for the human stress response and hypertension[J]. Endocr Rev, 1983, 4: 291-309.
[27] Missale C, Nash S.R, Robinson S.W, et al. Dopamine receptors: from structure to function[J]. Physiol Rev, 1998, 78: 189-225
[28] Jose P. A, Eisner G.M, Felder R. A. Role of dopamine receptors in the kidney in the regulation of blood pressure[J]. Curr Opin Nephrol Hypertens, 2002, 11: 87-92.
[29] Sanada H, Yao L, Jose P.A, et al. Dopamine D3 receptors in rat juxtaglomerular cells[J]. Clin Exp Hypertens, 1997, 9: 93-105.
[30] Luippold G, Schneider S, Vallon V, et al. Postglomerular vasoconstriction induced by dopamine D3 receptor activation in anesthetized rats[J]. Am J Renal Physiol, 2000, 278: 570-575.
[31] Gross M.L, Koch A, Mühlbauer B, et al. Renoprotective effect of a dopamine D3 receptor antagonist in experimental type II diabetes[J]. Lab Invest, 2006, 86: 262-274.
[32] Grundt P, Carlson E.E, Cao J, et al. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}ary-lcarbox-amides as selective probes with high affinity for the dopamine D3 receptor[J]. J Med Chem, 2005, 48(3): 839-848.
[33] Hackling A, Ghosh R, Perachon S, et al. N-(ω-(4-(2-Methoxyphenyl)- piperazin-1-yl)alky) carboxamides as dopamine D2 and D3 receptor ligands[J]. J Med Chem, 2003, 46(18): 3883-3899.
[34] Chu W, Tu Z, Elveen E. M, et al. Synthesis and in vitro binding of N-phenyl-piperazine analogs as potential dopamine D3 receptor ligands[J]. Bioorg Med Chem, 2005, 13(1): 77-87.
[35] Schlotter K, Boeckler F, Hubner H, et al. Fancy bioisosteres: metallocene-derived G-prot-ein-coupled receptor ligands with subnanomolar binding affinity and novel selectivity profiles[J]. J Med Chem, 2005, 48(11): 3696-3699.
[36] Murray P.J. A novel series of arylpiperazines with high affinity and selectivity for dopamine D3 receptor[J]. Bioorg Med Chem Lett, 1995, 5(1): 219-222.
[37] Millan M.J, Gobert A, Tancredi A. N, et al. S33084, a novel, potent, selective, and com-petitive antagonist at dopamine D3 receptors: I. receptorial, electrophysiological and neurochemical profile compared with GR218231 and L741626[J]. J Pharmacol Exp Ther, 2000, 293(3): 1048-1062.
[38] Nestler E.J. Common molecular and cellular substrates of addiction and memory[J]. Neurobiol Learn Mem, 2002, 78(3): 637-647.
[39] Audinot V, ancredi A. N, Gobert A, et al. A Comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists(+)-S 14297, afadotride, GR103,691 and U99194A[J]. J Pharmacol Exp Ther, 1998, 287(1): 187-197.
[40] Lenz C, Boeckler F, Hubner H, et al. Fancy bioisosteres: synthesis, SAR,and pharmacological investigations of novel nonaromatic dopamine D3 receptor ligands[J]. Bioorg Med Chem, 2005, 13(14): 4434-4442.
[41] Ding K., Wang S.M, et al. Enantiomerically pure hexahydropyrazinoquinolines as potent and selective dopamine 3 subtype receptor ligands[J]. J Med Chem, 2005, 48 (9): 3171-3181.
[42] Hobrath J.V, Wang S. M. Computational elucidation of the structural basis of ligand binding to the dopamine 3 receptor through Docking and homology modeling[J]. J Med Chem, 2006, 49 (15): 4470-4476.
[43] Boeckler F, Lanig H, et al. Modeling the similarity and divergence of dopamine D2-like receptors and identification of validated ligand?receptor complexes[J]. J Med Chem, 2005, 48 (3): 694-709.
[44] Ortore G, Tuccinardi T. A Theoretical study to investigate D2DAR/D4DAR selectivity: Receptor modeling and molecular docking of dopaminergic ligands[J]. J Med Chem, 2006, 49 (4):1397-1407.
[45] Xhaard H, Rantanen V.V, Nyrnen T. Molecular evolution of adrenoceptors and dopamine receptors: Implications for the binding of catecholamines[J]. J Med Chem, 2006, 49 (5): 1706-1719.
[46] Martin E. J., Blaney J.M., Siani M. A. et al. Measuring Diversity: Experimental Design of Combinatorial Libraries for Drug Discovery[J]. J Med Chem 1995, 38: 1431-1436.
[47] Spencer R.W. High-throughput screening of historic collections: Observations on file size, biological targets and file diversity[J]. Biotechnol Bioeng, 1998, 61: 61-67.
[48] Mary P. B, Xin C. Structure-based combinatorial library design: methodologies and applications[J]. J Mol Graph Mode, 2002, 20: 463-468.
[49]Valler M.J., Green D. Diversity screening versus focused screening in drug discovery [J]. Drug Discov Today, 2000, 5: 286-293.
[50] Zhan D, Claudio C, Juswinder S. Knowledge-Based design of target-focused libraries using protein?ligand interaction constraints[J]. J Med Chem, 2006, 49 (2): 490-500.
[51] Cheng C, Sean E, Praveen B, et al. Pharmacophore-based discovery of ligands for drug transporters[J]. Adv Drug Deliv Rev, 2006, 58: 1431-1450.
[52] Ferenc D, Gyrgy D, Papp K. Diversity measures for enhancing ADME admissibility of combinatorial libraries[J]. J Chem Inf Comput Sci, 2000, 40 (2): 314-322.
[53] Douglas A. H, Gregory T. B, Mark L. S. The combinatorial synthesis of bicyclic privileged structures or privileged substructures[J]. Chem Rev, 2003, 103 (3): 893-930.
[54] Robert P. S. Finding multiactivity substructures by mining databases of drug-Like compounds[J]. J Chem Inf Comput Sci, 2003, 43: 1037-1050.
[55] Daniel A. E, Robert S. M. Fragment-Based Drug Discovery[J]. J Med Chem, 2004, 47 (14): 3463-3482.
[56] Brian T.G, Dmytro O.T, Dana A. R, et al. Pyrazolo[1,5-a]pyrimidines. Identification of the privileged structure and combinatorial synthesis of 3-(Hetero)arylpyrazolo[1,5-a] pyrimidine-6-carbox amides[J]. J Comb Chem, 2007, 9 (3): 507-512.
[57] Britta C.S, Ulrich R. M, Jukka L. Hybrid approach for the design of highly affine and selective dopamine D3 receptor ligands using privileged scaffolds of biogenic amine GPCR ligands[J]. Bioorg Med Chem, 2007, 15: 7258-7273.
[58] Jonathan S.M, Brett R.B. Library design using BCUT chemistryspace descriptors and multiple fourpoint pharmacophore fingerprints: Simultaneous optimization and structure-based diversity[J]. J Mol Graph Model, 2000, 18: 438-451.
[59] Pickett, S.D. et al. Enhancing the hit-to-lead properties of lead optimization libraries[J]. J Chem Inf Comput Sci, 2000, 40: 263-272.
[60] Chen H. M, Brjesson U, Ola E, et al. ProSAR: A new methodology for combinatorial library design[J]. J. Chem. Inf. Model., 2009, 49 (3): pp 603-614.
[61] Henri X, Rantanen .V. V, Tommi N, et al. Molecular evolution of adrenoceptors and dopamine receptors: Implications for the binding of catecholamines[J]. J Med Chem, 2006, 49 (5):1706-1719.
[62] Francesca F, Pier G.. Benedetti. D., Computational modeling approaches to structure function analysis of G protein-coupled receptors[J]. Chem Rev, 2005, 105 (9): 3297-3351.
[63] Frank B, Peter G. The structural evolution of dopamine D3 receptor ligands: Structure-activity relationships and selected neuropharmacological aspects[J]. Pharmacol Ther, 2006,112: 281-333.
[64]杨日芳,恽榴红,多巴胺D3受体选择性配体研究进展,彭司勋主编,药物化学进展5,化学工业出版社,2007,90-108。
[65] Newman A.H, Peter G. Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents[J]. J Med Chem, 2005, 48(11):3664-3679.
[66] Karin S, Frank B. Fancy Bioisosteres: Metallocene-derived G-protein-coupled receptor ligands with subnanomolar binding affinity and novel selectivity profiles[J]. J Med Chem, 2005, 48, 3696-3699.
[67] Karin S, Frank B. Fancy Bioisosteres: Novel Paracyclophane Derivatives As Super-Affinity Dopamine D3 Receptor Antagonists[J]. J Med Chem, 2006, 49, 3628-3635
[68] Kent B, Michael A, Henning T, et al. Recognition of privileged structures by G-protein coupled receptors[J]. J Med Chem, 2004, 47 (4): 888-899.
[69] Robert P. Sheridan. Finding multiactivity substructures by mining databases of drug-like compounds[J], J. Chem. Inf. Comput. Sci., 2003, 43 (3): 1037-1050.
[70] Douglas A. Gregory H.T., Mark L.S. The combinatorial synthesis of bicyclic privileged structures or privileged substructures [J], Chem. Rev., 2003, 103(3): 893-930.
[71] Poupaert A, Carato P, Colacino E. 2(3H)-Benzoxazolone and bioisosters as "privileged scaffold" in the design of pharmacological probes [J], Curr Med Chem, 2005, 12, 877-885.
[72] Sakaguchi S., Shibamoto A., et al., Remarkable effect of nitrogen dioxide for N-hydroxyphthalimide-catalyzed aerobic oxidation of methylquinolines[J], Chem. Commu., 2002, 180-182.
[73]. Dumouchel S., Mongin F., et al. Tributylmagnesium ate complex mediated bromine-magnesium exchange of bromoquinolines: a convenient access to functionalized quinolines [J], Tetrahedron. Lett., 2003, 44, 2033.
[74]. Peter B, Anthony T. Total synthesis of methoxatin, the coenzyme of methanol dehydrogenase and glucose de hydrogenase[J], J. Org. Chem, 1981, 46 (21): 4317-4320.
[75]. Senear A.E., Mead J.F., The synthesis of potential antimalarials[J], J. Am. Chem. Soc., 1946, 68, 2695-2698.
[76]. Carrigan C.N., Richard D.B, et al. Synthesis and in vitro pharmacology of substituted quinoline-2,4-dicarboxylic acids as inhibitors of vesicular glutamate transport[J], J. Med. Chem. 2002, 45, 2260-2276.
[77] Ashry, Sayed H.E., Ramadan E, et al. Microwave-assisted synthesis of quinoline derivatives from Isatin[J], Synth Commu, 2005, 35(17): 2243 -2250.
[78] WILKINSON G, Ferrocene: Iron, dicyclopentadienyl [J], org. Synth.,1963, 4, 472-476.
[79] .Gottlieb K J, et al. Ferrocene compounds. US 5717122.1998
[80].Viktor W, Landenberg P, et al. Carboxycyclopentadienyl iron. US 2683157.1954
[81].Perry C.R. Carboxylation of aromatic compounds: ferrocenecarboxylic acid[J]. Org Synth, 1988, 56, 28-29.
[82]. Jaime C, JoséC, Rosa F, A convenient route to 2-substituted benzothiazole-6-carboxylic acids using nitrobenzene as oxidant [J]. J Chem Res, 2006, 12, 769-770.
[83]. Hiroharu M, Nobuhiro O, Masahiko M, Antirheumatic agents: novel methotrexate derivatives bearing a benzoxazine or benzothiazine Moiety[J], J Med Chem, 1997, 40, 105-111.
[84].Bernd S. Reaction of ferrocenecarboxylic acid with N, N-disubstituted carbodiimides[J]. J Org Chem, 689 (2004) 1472-1480
[85] Vieth M, Siegel M.G, Higgs R. E, et al. Characteristic physical properties and structural fragments of marketed oral drugs [J]. J Med Chem, 2004, 47: 224-228.
[86] Henchoz Y, Guillarme D, Rudaz S, et al. High-throughput log P determination by ultraperformance liquid chromatography: A convenient tool for medicinal chemists [J]. J Med Chem, 2008, 51: 396-399.
[87] Waterbeemd H.D, Kansy M, Wagner B, et al. Lipophilicity in drug action and toxicology [M]. Weinheim: VCH Publishers, 1996: 311-337.
[88] Deborah B, Grushka E. Effect of n-octanol in the mobile phase on lipophilicity determination by reversed-phase high-performance liquid chromatography on a modified silica column [J]. J Chromatogr A, 2008, 1209: 111-119.
[89] Costas G, Stamatios T, Anna TK, et al. Contribution to the standardization of the chromatographic conditions for the lipophilicity assessment of neutral and basic drugs [J]. Analytica Chimica Acta, 2006, 573: 311-318.
[90] Costas G, Stamatios T, Anna T.K, et al. Octanol/water partitioning simulation by reversed-phase high performance liquid chromatography for structurally diverse acidic drugs: Effect of n-octanol as mobile phase additive [J]. J Chromatogr A, 2007, 1166: 116-125.
[91] Lombardo F, Shalaeva M.Y, Tupper KA, et al. ElogDoct: A tool for lipophilicity determination in drug discovery [J]. J Med Chem, 2001, 44: 2490-2497.
[92]. Liu X.L, Hideji T, Yamauchi A. Determination of lipophilicity by reversed-phase high-performance liquid chromatography Influence of 1-octanol in the mobile phase [J]. J Chromatogr A, 2005, 1091: 51-59.
[93] Cecchi T, Passamontib P. Retention mechanism for ion-pair chromatography with chaotropic reagents [J]. J Chromatogr A (in press, CHROMA-349357).
[94] Flieger, R. Application of chaotropic effect in reversed-phase liquid chromatography of structurally related phenothiazine and thioxanthene derivatives [J]. J Chromatogr A, 2008,1192: 218-224.
[95] Hisham H, Thomas J. Effect of chaotropic mobile phase additives on retention behaviour of beta-blockers on various reversed-phase high-performance liquid chromatography columns [J]. J Chromatogr A, 2006, 1133: 69-75.
[96] Judith V.H, Wang S.M. Computational elucidation of the structural basis of ligand binding to the dopamine D3 receptor through docking and homology modeling[J]. J Med Chem, 2006, 49 (15): 4470-4476.
[97] Boeckler F, Lanig H, Gmeiner P. Modeling the similarity and divergence of dopamine D2-like receptors and identification of validated ligand-receptor complexes[J]. J Med Chem, 2005, 48 (3): 694-709.
[98] Ortore G, Tuccinardi T, Bertini S, et al. A theoretical study to investigate D2DAR/D4DAR selectivity: Receptor modeling and molecular docking of dopaminergic ligands[J]. J Med Chem, 2006, 49 (4): 1397-1407.
[99] Filteau, F., Veilleux, F., Levesque D. Effects of reciprocal chimeras between the C-terminal portion of third intracellular loops of the human dopamine D2 and D3 receptors[J]. FEBS Lett., 1999, 447: 251-256.
[100] Sali, A, Blundell, T.L. Comparative protein modeling by satisfaction of spatial restraints[J]. J Mol Biol, 1993, 234: 779-815.
[101] Varady J, Wu X.H, Fang X.L, et al. Molecular modeling of the three- dimensional structure of dopamine 3 (D3) subtype receptor: discovery of novel and potent D3 ligands through a hybrid pharmacophore- and structure-based database searching approach[J]. J Med Chem, 2003, 46 (21): 4377-4392.
[102] Shi L, Jonathan A.J. The binding site of aminergic G protein-coupled receptors: The transmembrane segments and second extracellular loop[J]. Ann Rev Pharmacol Toxicol, 2002, 42: 437-467.
[103] Shi, L., Javitch, J. The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop[J]. Ann Rev Pharmacol Toxicol, 2002, 42: 437-467.
[104] Cerius2, a molecular modeling system, supplied by Accelrys Inc., San Diego, CA.
[105] Weinstock J, Gaitanopoulos D.E., Stringer O.D., et al. Synthesis and evaluation of non-catechol D1 and D2 dopamine receptor agonists: benzimidazol-2-one, benzoxazol-2-one, and the highly potent: benzothiazol-2-one 7-ethylamines[J]. J. Med. Chem., 1987, 30 (7), 1166-1176.